Vladimira Vasileva Boyadzhieva (Vladimira Boyadzieva, Vladimira Boyadzhieva)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Rheumatoid Arthritis

Disease Activity

Prognostic Factors

Coronavirus Disease

Top Venues

Rheumatology international

Healthcare (Basel, Switzerland)

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Zornitsa Mitkova, Ivan Manev, Konstantin Tachkov, Vladimira Vasileva Boyadzhieva, Nikolay Stoilov, Miglena Doneva, Guenka Petrova
How Managed Entry Agreements Influence the Patients' Affordability to Biological Medicines-Bulgarian Example. Healthcare (Basel, Switzerland) 11 (17) (2023)
Rositsa Dacheva, Ekaterina Krasimirova Kurteva, Vladimira Vasileva Boyadzhieva, Rumen Stoilov, Dobroslav Kyurkchiev, Nikolay Stoilov
A Rare Case of Anca Positivity and Antiphospholipid Antibodies in a Patient with Takayasu Arteritis: Case Report and Review of the Literature. Biomedicines 11 (10) (2023)
Vladimira Vasileva Boyadzhieva, Konstantin Tachkov, Nikolay Rumenov Stoilov, Konstantin Mitov, Rumen Malinov Stoilov, Guenka Petrova
Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies. Rheumatology international 42 (10) (2022)
Konstantin Tachkov, Zornitsa Mitkova, Vladimira Vasileva Boyadzhieva, Guenka Petrova
Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. Pharmaceuticals (Basel, Switzerland) 14 (1) (2021)
Vladimira Vasileva Boyadzhieva, Nikolay Rumenov Stoilov, Rumen Malinov Stoilov
Coronavirus disease 2019 (COVID-19) during pregnancy in patients with rheumatic diseases. Rheumatology international 40 (11) (2020)
Ekaterina Krasimirova Kurteva, Vladimira Vasileva Boyadzhieva, Nikolay Rumenov Stoilov
Systemic sclerosis in mother and daughter with susceptible HLA haplotype and anti-topoisomerase I autoantibodies. Rheumatology international 40 (6) (2020)